Sentry Investment Management LLC Trims Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Sentry Investment Management LLC lowered its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 14.0% during the 4th quarter, HoldingsChannel reports. The fund owned 14,936 shares of the medical equipment provider’s stock after selling 2,432 shares during the period. Sentry Investment Management LLC’s holdings in AxoGen were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of AxoGen during the 4th quarter valued at $235,000. Bradley Foster & Sargent Inc. CT grew its holdings in AxoGen by 3.7% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 84,153 shares of the medical equipment provider’s stock valued at $1,387,000 after buying an additional 2,989 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of AxoGen during the fourth quarter valued at about $519,000. New York State Common Retirement Fund lifted its holdings in shares of AxoGen by 63.7% in the fourth quarter. New York State Common Retirement Fund now owns 69,629 shares of the medical equipment provider’s stock worth $1,147,000 after buying an additional 27,101 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of AxoGen by 8.3% in the fourth quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider’s stock worth $264,000 after buying an additional 1,228 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group boosted their price objective on shares of AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

AxoGen Price Performance

NASDAQ:AXGN opened at $20.11 on Wednesday. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $21.00. The stock has a fifty day moving average of $17.47 and a 200 day moving average of $14.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market capitalization of $885.09 million, a price-to-earnings ratio of -62.85 and a beta of 1.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.